These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 36332638)
1. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss. Furqan F; Shah NN Annu Rev Med; 2023 Jan; 74():279-291. PubMed ID: 36332638 [TBL] [Abstract][Full Text] [Related]
2. Bispecific CAR T-cells for B-cell Malignancies. Furqan F; Shah NN Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589 [TBL] [Abstract][Full Text] [Related]
4. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647 [TBL] [Abstract][Full Text] [Related]
5. Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently. Chen Z; Liu Y; Chen N; Xing H; Tian Z; Tang K; Rao Q; Xu Y; Wang Y; Wang M; Wang J Sci China Life Sci; 2023 Apr; 66(4):754-770. PubMed ID: 36251156 [TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577 [TBL] [Abstract][Full Text] [Related]
8. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. Leung I; Templeton ML; Lo Y; Rajan A; Stull SM; Garrison SM; Salter AI; Smythe KS; Correnti CE; Srivastava S; Yeung CCS; Riddell SR Blood Adv; 2023 Jun; 7(12):2718-2730. PubMed ID: 36469024 [TBL] [Abstract][Full Text] [Related]
9. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862 [TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma]. Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437 [No Abstract] [Full Text] [Related]
13. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474 [TBL] [Abstract][Full Text] [Related]
15. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. Kokalaki E; Ma B; Ferrari M; Grothier T; Hazelton W; Manzoor S; Costu E; Taylor J; Bulek A; Srivastava S; Gannon I; Jha R; Gealy R; Stanczuk L; Rizou T; Robson M; El-Kholy M; Baldan V; Righi M; Sillibourne J; Thomas S; Onuoha S; Cordoba S; Pule M Mol Ther; 2023 Jul; 31(7):2089-2104. PubMed ID: 36945773 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185 [TBL] [Abstract][Full Text] [Related]
18. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641 [TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Abramson JS; Lunning M; Palomba ML Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671 [TBL] [Abstract][Full Text] [Related]
20. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]